Juventas Lead Compound Successfully Completes Phase I Trial
Cleveland, OH--Juventas Therapeutics has successfully completed its Phase I clnical trial to evaluate the safety and preliminary efficacy of its lead compound, JVS-100, for the treatment of patients with heart failure. The Company is developing a platform to regenerate damaged tissue by using JVS-100 to recruit stem cells to the site of injury, with an initial focus on cardiovascular disease.
The trial enrolled 17 NYHA Class III heart failure patients who had left ventricular ejection fractions of less than 40% and were an average of 7.3 years post-heart attack. JVS-100 encodes Stromal-cell Derived Factor 1 (SDF-1) a signalling protein that recruits stem cells to the site of injured tissue. SDF-1 is naturally produced following an acute injury, but production of it shuts shown shortly after the acute injury. Juventas is demonstrating that injured tissue can be repaired months or years later with the therapeutic introduction of JVS-100. Read more...
Find Out More About ESP
Early Stage Partners Managing Director Mike Bunker serves on the Juventas board.